Drug Approval | June 22, 2024
Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
ORACEA is a trademark of Galderma Holdings, S.A.
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Lupin has been exclusively marketing these brands in the Indian market since July 2021
Eris Lifesciences enters into term loan agreement with Citi Bank
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Subscribe To Our Newsletter & Stay Updated
